Stocks and Investing
Stocks and Investing
Mon, May 20, 2019
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Fri, May 17, 2019
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Thu, May 16, 2019
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Joel Beatty Maintained (SRPT) at Strong Buy with Decreased Target to $190 on, May 16th, 2019
Joel Beatty of Citigroup, Maintained "Sarepta Therapeutics, Inc." (SRPT) at Strong Buy with Decreased Target from $201 to $190 on, May 16th, 2019.
Joel has made no other calls on SRPT in the last 4 months.
There are 4 other peers that have a rating on SRPT. Out of the 4 peers that are also analyzing SRPT, 0 agree with Joel's Rating of Hold.
These are the ratings of the 4 analyists that currently disagree with Joel
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $165 on, Tuesday, May 14th, 2019
- Brian Abrahams of "RBC Capital" Maintained at Buy with Decreased Target to $188 on, Thursday, May 9th, 2019
- Christopher Marai of "Nomura" Maintained at Strong Buy with Increased Target to $230 on, Thursday, February 28th, 2019
- Alethia Young of "Cantor Fitzgerald" Maintained at Buy with Increased Target to $231 on, Thursday, February 28th, 2019